Ana de Carvalho

Ana deCarvalho, PhD, is an Associate Scientist in the Dept. of Neurosurgery and the director of the Hermelin Brain Tumor Center Live Biobank, at Henry Ford Health (HFH). She serves as Associate Professor-Research in the Dept. of Physiology, MSU College of Human Medicine, and as Adjunct Associate Professor in the Dept. of Pharmacology, Wayne State University School of Medicine.  Dr. deCarvalho has cultivated a wide range of local, national and international collaborators with the common goal of dissecting the biology and improving treatments for brain tumors. She holds a PhD in Biology from Florida State University and has completed postdoctoral training in Developmental Biology at Florida State University and in Experimental Therapeutics at HFH.

Research: 
Outcomes remain poor for many brain tumor patients, especially those with high-grade gliomas like glioblastoma, despite intensive treatment, including surgery, radiation, and chemotherapy.
Our research team develops, characterizes, and banks patient-derived brain tumor models for preclinical studies. Using these clinically relevant models, we investigate the multifaceted drivers of malignancy and treatment resistance in high-grade gliomas. To advance patient outcomes, we prioritize therapeutic target validation amid the complex challenges of co-activated oncogenic pathways, extensive tumor heterogeneity, and cellular plasticity.